Newsroom

LONDON--(BUSINESS WIRE)--Saba Capital Management, L.P. (together with certain of its affiliates, “Saba” or “we”), a significant shareholder of BlackRock Throgmorton Trust plc (THRG:LSE) and BlackRock Smaller Companies Trust plc (BRSC:LSE) (together with THRG, the “Companies”), today issued the following statement regarding the Companies’ proposed combination. “Saba welcomes today’s announcement, which includes several shareholder-friendly initiatives for the combined company such as reduced man...

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 19 February 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback   Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 19 February 2026 Number of Public Shares Purchased:...

NEW YORK--(BUSINESS WIRE)--  20th February 2026 RE-ISSUE OF TREASURY SHARES CRH plc announces that on 19th February 2026 it transferred 2,314,728 Ordinary Shares at a price of $124.75 per Ordinary Share to the Trustees of the CRH plc Employee Benefit Trust for the purpose of satisfying vested awards made under the CRH 2014 Performance Share Plan. Following the above transaction, CRH plc holds 35,661,896 Ordinary Shares in Treasury. The number of Ordinary Shares in issue (excluding Treasury Shar...

DUESSELDORF, Germany--(BUSINESS WIRE)--Global retail solutions provider SOLUM and EWQ expand strategic partnership at EuroShop 2026 to deliver integrated in-store digital communication...

LONDON--(BUSINESS WIRE)--  20 February 2026 YOUNG & CO.’S BREWERY, P.L.C. Transaction in own shares Young & Co.’s Brewery, P.L.C. (the “Company”) announces that on 19 February 2026, in accordance with the terms of its share buyback programme announced by the Company on 17 November 2025 (the “Share Buyback Programme”), it has purchased the following Non-voting ordinary shares of 12.5 pence each (“Non-voting Shares” and the “Purchased Shares”) in the Company through Stifel Nicolaus Europe...

DALLAS--(BUSINESS WIRE)--Kosmos Energy (NYSE/LSE: KOS) (“Kosmos” or the “Company”) is pleased to confirm that the license extensions for the West Cape Three Points and Deepwater Tano Petroleum Agreements, which cover the Jubilee and TEN fields in Ghana, have been formally ratified by the Ghanaian parliament. The licenses now extend to 2040. The license extensions bring key benefits to Ghana including up to $2 billion in incremental investment as well as higher volumes of affordable gas from the...

PARIS--(BUSINESS WIRE)--2025 results above expectations. Solid outlook for 2026....

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the combination regimen of Venclexta® (venetoclax) plus acalabrutinib for the treatment of previously untreated adults with chronic lymphocytic leukemia (CLL), based on results from the Phase III AMPLIFY study. “Today’s approval represents an important step forward for people newly diagnosed with chronic...

PARIS--(BUSINESS WIRE)--Regulatory News: Orano: Chiffre d’affaires au-dessus de 5 milliards d’euro et taux d’EBITDA élevé, en progression par rapport à 2024 retraité de la contribution ponctuelle de contrats avec des électriciens japonais dans l’Aval Chiffre d’affaires de 5 138 M€ soutenu par des volumes vendus en progression dans la Mine et des productions en hausse dans l’Aval Taux d’EBITDA de 26,9% porté par le bon fonctionnement des usines Base comparable élevée (5 874 M€ de chiffre d’affai...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application for giredestrant, an investigational oral therapy, in combination with everolimus for the treatment of adult patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer follow...